Related Experiment Video

Updated: May 20, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

β1 adrenergic receptor polymorphisms and heart failure: a meta-analysis on susceptibility, response to β-blocker

Wen-Nan Liu1, Kai-Li Fu, Hai-Yang Gao

  • 1Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Public Health, Ji'nan, People's Republic of China.

Plos One
|July 21, 2012
PubMed

Insights

The Gly389 allele impacts heart failure (HF) risk differently in East Asians and whites. Arg389 homozygotes show better response to beta-blocker therapy but do not predict HF prognosis.

Area of Science:

  • Cardiovascular Genetics
  • Pharmacogenomics
  • Heart Failure Research

Background:

  • Heart failure (HF) risk stratification and predicting beta-blocker response are challenging.
  • Beta-1 adrenergic receptor (β1-AR) plays a key role in HF.
  • Previous studies on β1-AR polymorphisms (Ser49Gly, Arg389Gly) and HF have yielded inconsistent results.

Purpose of the Study:

  • To evaluate the impact of β1-AR polymorphisms on HF susceptibility.
  • To assess the influence of these polymorphisms on beta-blocker therapy response.
  • To determine the association between β1-AR polymorphisms and HF prognosis.

Main Methods:

  • Systematic search of electronic databases up to August 2011.
  • Meta-analysis of data from 27 eligible studies.
  • Standardized data extraction and analysis methods were employed.

Main Results:

  • In East Asians, Gly389 allele/homozygotes increased HF risk; in whites, they trended to decrease risk.
  • Arg389 homozygotes demonstrated a better response to beta-blocker therapy.
  • Arg389 homozygotes showed improved LVEF in East Asians and mixed populations, and LV volumes in whites.
  • No significant impact of Ser49Gly polymorphism on HF risk or prognosis was observed.
  • HF prognosis was similar for Arg389 homozygotes and Gly389 carriers.

Conclusions:

  • Gly389 allele/homozygotes are HF risk factors in East Asians but may protect whites.
  • Arg389 homozygote is associated with favorable beta-blocker response in HF patients.
  • Neither polymorphism independently predicts HF prognosis.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...